×
About 6,677 results

ALLMedicine Familial Hypercholesterolemia Center

Research & Reviews  2,573 results

Clinical Pharmacology of Statins: an Update.
https://doi.org/10.1007/s11883-020-00844-w
Current Atherosclerosis Reports; Ferri N, Corsini A

Jun 2nd, 2020 - Statins represent the cornerstone for the treatment of hypercholesterolemia, although muscle-related side effects and dysregulation of glucose metabolism have strongly limited their adherence and compliance especially in primary prevention therapy...

What Is Familial Hypercholesterolemia, and Why Does It Matter?
https://doi.org/10.1161/CIRCULATIONAHA.120.046961
Circulation Khera AV, Hegele RA

Jun 1st, 2020 - What Is Familial Hypercholesterolemia, and Why Does It Matter?|2020|Khera AV,Hegele RA,|

Intravascular ultrasound imaging of isolated and non aorto-ostial coronary Takayasu art...
https://doi.org/10.1186/s12872-020-01541-x
BMC Cardiovascular Disorders; Shimizu T, Sato A et. al.

May 31st, 2020 - Isolated coronary Takayasu arteritis is a rare form of ischemic heart disease that typically appears as an aorto-ostial lesion. Although several vascular imaging modalities including ultrasonography, computed tomographic angiography, magnetic reso...

Prevalence of Familial Hypercholesterolemia Among the General Population and Patients W...
https://doi.org/10.1161/CIRCULATIONAHA.119.044795
Circulation Hu P, Dharmayat KI et. al.

May 29th, 2020 - Contemporary studies suggest that familial hypercholesterolemia (FH) is more frequent than previously reported and increasingly recognized as affecting individuals of all ethnicities and across many regions of the world. Precise estimation of its ...

Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hype...
https://doi.org/10.1016/j.jacc.2020.03.065
Journal of the American College of Cardiology; Trinder M, DeCastro ML et. al.

May 28th, 2020 - Lipoprotein(a) is an atherogenic low-density lipoprotein-like particle and circulating levels are largely determined by genetics. Patients with familial hypercholesterolemia (FH) have elevated lipoprotein(a); however, it remains unclear why. This ...

see more →

Guidelines  5 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: Clinical Summary
https://allmedx.com/USPSTFPDF/lipidscreening_ch-summary.pdf

Aug 2nd, 2016 - Figure. Screening for Lipid Disorders in Children and Adolescents: Clinical Summary Population Asymptomatic children and adolescents 20 years or younger Recommendation No recommendation. Grade: I (insufficient evidence) Ri...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 17th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

NEXLETOL™ (bempedoic acid) - A New Treatment Option‎
https://www.nexletolhcp.com/

Discover How NEXLETOL May Help Appropriate Patients. See Important Safety Information and Full Prescribing Information. Learn About New Treatment. FDA Approved. Get The Facts.

see more →

Drugs  317 results see all →

Clinicaltrials.gov  3,309 results

Fast Five Quiz: Heterozygous Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/930068

Jun 2nd, 2020 - Familial hypercholesterolemia (FH) is a common but underdiagnosed and undertreated genetic disorder that affects individuals of all races and ethnicities. Several forms of FH have been identified. Heterozygous FH, the most common type, occurs when...

Fast Five Quiz: Heterozygous Familial Hypercholesterolemia Presentation and Diagnosis
https://www.medscape.com/viewarticle/930070

Jun 2nd, 2020 - Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that results in elevated blood cholesterol levels and a markedly increased risk for atherosclerosis and premature coronary artery disease. Although it is commonly perceiv...

Clinical Pharmacology of Statins: an Update.
https://doi.org/10.1007/s11883-020-00844-w
Current Atherosclerosis Reports; Ferri N, Corsini A

Jun 2nd, 2020 - Statins represent the cornerstone for the treatment of hypercholesterolemia, although muscle-related side effects and dysregulation of glucose metabolism have strongly limited their adherence and compliance especially in primary prevention therapy...

What Is Familial Hypercholesterolemia, and Why Does It Matter?
https://doi.org/10.1161/CIRCULATIONAHA.120.046961
Circulation Khera AV, Hegele RA

Jun 1st, 2020 - What Is Familial Hypercholesterolemia, and Why Does It Matter?|2020|Khera AV,Hegele RA,|

Intravascular ultrasound imaging of isolated and non aorto-ostial coronary Takayasu art...
https://doi.org/10.1186/s12872-020-01541-x
BMC Cardiovascular Disorders; Shimizu T, Sato A et. al.

May 31st, 2020 - Isolated coronary Takayasu arteritis is a rare form of ischemic heart disease that typically appears as an aorto-ostial lesion. Although several vascular imaging modalities including ultrasonography, computed tomographic angiography, magnetic reso...

see more →

News  469 results

Fast Five Quiz: Heterozygous Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/930068

Jun 2nd, 2020 - Familial hypercholesterolemia (FH) is a common but underdiagnosed and undertreated genetic disorder that affects individuals of all races and ethnicities. Several forms of FH have been identified. Heterozygous FH, the most common type, occurs when...

Fast Five Quiz: Heterozygous Familial Hypercholesterolemia Presentation and Diagnosis
https://www.medscape.com/viewarticle/930070

Jun 2nd, 2020 - Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that results in elevated blood cholesterol levels and a markedly increased risk for atherosclerosis and premature coronary artery disease. Although it is commonly perceiv...

Alirocumab Effective in Homozygous FH
https://www.medscape.com/viewarticle/927882

Mar 30th, 2020 - Alirocumab achieved a mean 63-mg/dL reduction in LDL cholesterol in the ODYSSEY HoFH study, the largest-ever randomized, placebo-controlled clinical trial of lipid-lowering in adults with homozygous familial hypercholesterolemia (HoFH), Dirk Blom,...

New Lipid-lowering Drug Class Slashes LDL in HoFH Patients
https://www.medscape.com/viewarticle/927862

Mar 30th, 2020 - Evinacumab, the first agent from a new class of lipid-lowering drugs, showed a "remarkable" and unprecedented level of LDL-cholesterol lowering in a pivotal trial with 65 patients with homozygous familial hypercholesterolemia. Monthly intravenous ...

New lipid-lowering drug class slashes LDL in HoFH patients
https://www.mdedge.com/fedprac/article/219837/lipid-disorders/new-lipid-lowering-drug-class-slashes-ldl-hofh-patients?channel=53
Mitchel L. Zoler

Mar 30th, 2020 - Evinacumab, the first agent from a new class of lipid-lowering drugs, showed a “remarkable” and unprecedented level of LDL-cholesterol lowering in a pivotal trial with 65 patients with homozygous familial hypercholesterolemia. Dr.

see more →

Patient Education  4 results see all →